Clinical Trials
33 trialsMOLTHY
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML
Assiut University
Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344
Alliance for Clinical Trials in Oncology
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
Assiut University
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
OHSU Knight Cancer Institute
Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy
Eastern Cooperative Oncology Group
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
Vanderbilt University Medical Center
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma
Alliance for Clinical Trials in Oncology
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
Children's Oncology Group
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Biomarkers in Patients With Rhabdomyosarcoma
Children's Oncology Group
DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers
Children's Oncology Group
Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors
Children's Oncology Group
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer
Memorial Sloan Kettering Cancer Center
Lapatinib Resistance in Patients With Breast Cancer
Case Comprehensive Cancer Center
Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial
NSABP Foundation Inc
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
SWOG Cancer Research Network
S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
SWOG Cancer Research Network
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
Case Comprehensive Cancer Center
Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors
Children's Oncology Group
Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507
Case Comprehensive Cancer Center
Spectroscopy of Breast Tissue
Case Comprehensive Cancer Center
Proteases in Patients With Prostate Cancer That Has Spread to the Bone
Barbara Ann Karmanos Cancer Institute
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Study of Ductal Lavage in Women at High Risk for Breast Cancer
University of California, San Francisco
IRB 2000-294
University of Michigan Rogel Cancer Center
Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer
National Cancer Institute (NCI)
Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients
Istituto Clinico Humanitas
Level of HER2-neu Gene Amplification an Response to Trastuzumab
Istituto Clinico Humanitas
Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab
Istituto Clinico Humanitas